John Marshall, MD
Lombardi Cancer Center
Georgetown University
Washington, DC, USA
Alberto Sobrero, MD
Hospital San Martino
Genoa, Italy
Faculty:
Dirk Arnold, MD
Martin Luther University
Halle, Germany
David Cunningham, MD Royal Marsden Hospital
Surrey, United Kingdom
Edward Chu, MD Yale Cancer Center
Yale University
New Haven, Connecticut, USA
David Ilson, MD, PhD Memorial Sloan-Kettering Cancer Center
New York, New York, USA
Axel Grothey, MD Mayo Clinic
Rochester, Minnesota, USA
Christopher Twelves, MD
Leeds Cancer Center
St James’s University Hospital
Leeds, United Kingdom
Agenda
Welcome and Introduction
Co-chairs: John Marshall, MD
Alberto Sobrero, MD
25 mins
Debate I
What Constitutes Optimal Initial CHEMOTHERAPY for Metastatic Colorectal Cancer in a Patient with Good Performance Status?
FOLFOX or FOLFIRI: David Ilson, MD, PhD
XELOX or XELIRI: Alberto Sobrero, MD
5 mins
Panel Commentary
25 mins
Debate II
Should Chemotherapy plus a Targeted Agent Be the New Standard for Initial Management of Metastatic Colorectal Cancer?
PRO: Edward Chu, MD
CONTRA: Dirk Arnold, MD
5 mins
Panel Commentary
25 mins
Debate III
What Is the Best Multidisciplinary Approach to Resectable Gastric Cancer?
Perioperative Chemotherapy: David Cunningham, MD
Postoperative Chemoradiotherapy: John Marshall, MD
5 mins
Panel Commentary
25 mins
Debate IV
Capecitabine-Based Adjuvant Chemotherapy
(+/- Bevacizumab) is Preferred to 5FU-Based Chemotherapy
(+/- Bevacizumab) for Stage II/III Colorectal Cancer.
PRO: Christopher Twelves, MD
CONTRA: Axel Grothey, MD
5 mins
Panel Commentary
Concluding Remarks
Co-chairs: John Marshall, MD
Alberto Sobrero, MD
Target Audience
Dilemmas in Colorectal and Gastric Cancer Management: Global Perspectives is intended for medical oncologists, radiation oncologists, surgeons, and other healthcare providers interested in the management of colorectal and gastric cancer.
Educational Objectives
After successfully completing this educational activity, participants should be able to:
Outline data from recent clinical trials involving combination chemotherapy regimens for initial treatment of patients with metastatic colorectal cancer
Describe recent clinical trial data integrating antiangiogenic agents and EGFR inhibitors into chemotherapy regimens for the initial management of metastatic colorectal cancer
Explain the association between the KRAS mutational status and efficacy of available anti-EGFR agents so that the appropriate choice of targeted agents may be selected for specific patients
Identify the optimal multidisciplinary approach to resectable gastric cancer based on recent clinical trial evidence
Review current and emerging regimens for adjuvant treatment of patients with Stage II/III colorectal cancer including considerations that might be taken into account when selecting therapeutic regimens
To participate in this activity, your computer should have a processor the equivalent of Intel Pentium II 450 MHz or faster, with 128MB of RAM and a connection to the internet.
Support Statement
This activity is supported by an educational grant from Roche Laboratories Inc.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published or and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. PRIME Oncology or Roche Laboratories Inc do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PRIME Oncology or Roche Laboratories Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Statement
Not an official event of the ASCO meeting. Not sponsored or endorsed by ASCO or The ASCO Cancer Foundation.
